News

Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.

Resistance is expected to worsen significantly, but can a combination of both ground-level clinician stewardship actions as well as systemic reforms such as the Pasteur Act at least slow down the train?

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

A hematologist discusses the role of internal and family medicine practitioners in improving the diagnosis and management of iron deficiency.

Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.

In this video, a hematologist discusses trials and areas of advancement he is excited about in the current landscape.

In part 2 of our 5-part series, Steven Fein, MD, discusses updates in iron deficiency management from 2024.

In this video, Steven Fein, MD, discusses updates and topics of note from the American Society of Hematology annual meeting.

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

These findings highlight the safety and effectiveness of ESO-101 among adult patients with active eosinophilic esophagitis (EoE).

A study shows young adults with negative emotionality, particularly alienation, who experienced childhood adversities often experience more stressful life events in adulthood.

Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.

The Boxed Warning is based on the FDA’s review of a postmarketing case of serious liver injury with fezolinetant reported to the FAERS database.

The FDA has accepted the NDA for TNX-102 SL, a non-opioid, centrally acting analgesic, for the bedtime treatment of fibromyalgia; the PDUFA date still needs to be assigned.

This interview featured a discussion with Browning regarding his team’s findings prior to the FDA approval of tapinarof cream 1% for atopic dermatitis.

Laurence Sperling, MD described the evolving role of cardiologists in obesity care, particularly with the increasing adoption of therapies such as GLP-1 agonists.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

Laurence Sperling, MD shares insights into a multi-disciplinary approach to the management of obesity from the perspective of a cardiologist.

Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

In this episode, hosts reflect on the advancement in CGM that reshaped care for diabetes and overall health during 2024.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Machine learning models improve accuracy in detecting MASH with F2-F3 fibrosis, surpassing noninvasive tests in sensitivity, specificity, and predictive value.